Systemic Therapy for Colon Cancer
Systemic Therapy for Colon Cancer
复制标题
DOI：
10.1016/j.soc.2017.11.001
复制
发表时间：
2018-04-01
影响因子：
1.9
通讯作者：
Wu, Christina
中科院分区：
文献类型：
--
作者：
Wu, Christina
结肠癌患者的全身治疗已经广泛扩展到5-氟尿嘧啶为基础的化疗。对于正在考虑辅助化疗的早期结肠癌患者，必须考虑多种因素，如疾病复发风险、化疗的绝对生存获益、治疗毒性和患者合并症。在转移性背景下，生物标志物如KRAS/NRAS/BRAF突变，微卫星不稳定性状态和左侧与右侧结肠癌帮助肿瘤学家定制全身治疗方案，包括化疗，靶向治疗和免疫治疗。
Systemic treatments for patients with colon cancer has expanded broadly beyond 5-fluorouracil-based chemotherapy. For patients with early-stage colon cancer who are considering adjuvant chemotherapy, multiple factors such as the risk of disease recurrence, absolute survival benefit of chemotherapy, treatment toxicity, and patient comorbid medical conditions must be taken into account. In the metastatic setting, biomarkers such as KRAS/NRAS/BRAF mutation, microsatellite instability status, and left- versus right-sided colon cancer have helped oncologists to tailor systemic treatment regimens, which include chemotherapy, targeted therapy, and immunotherapy.